Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 4 · 80%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 0 · 0%

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every 4 weeks showed no clear difference in proportion of all‐cause mortality at ≥ 12 months compared with placebo (moderate certainty).

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
RR 0.17 [0.01, 3.94]
1 study · 30 participants
Moderate

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found